Development of Risk-Adjusted Outcome Measures in the EHR Environment
EHR 环境中风险调整结果措施的制定
基本信息
- 批准号:8259360
- 负责人:
- 金额:$ 4.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-30 至 2012-09-29
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
We are proposing to hold an invitational conference to examine issues related to the identification and development of outcome measures, and their accompanying risk adjustment models, in the electronic health record (EHR) environment. This conference will address methodological issues that will form the basis for a demonstration project to develop risk- adjusted outcome measures generated from the EHR. These risk-adjusted outcome measures would be useful for oversight, internal quality improvement, public reporting, pay-for- performance and consumer decision-making. Outcome measures assess the results of the patient's health care system encounter, and they are particularly useful for evaluating the quality of that care. Due to difficulties in locating and collecting accurate and comprehensive data on health outcomes, performance measurement efforts have primarily focused on the processes of care. Yet, in most areas, the relationship between the processes of care being measured and specific health outcomes has yet to be established. The introduction of the EHR across the broad spectrum of health care is expected to provide new opportunities to access and gather data upon which outcome measures can be based. In order to accurately compare performance across providers and over time outcome measures require risk adjustment. The quality and usefulness of an outcome measure depends on the quality of the risk adjustment model accompanying it. Widespread EHR implementation holds the promise of supplying more and better data upon which to construct these models. The following questions will be explored at the conference. (1) How can EHR data be used to develop risk models for existing mortality and readmission outcome measures? (2) What EHR data originating from outside the hospital walls will be useful for the development of risk adjusted outcome measures in the hospital setting, and in settings outside of the hospital? (3) What new risk adjusted outcome measures (beyond mortality and readmission rates) can be generated through the use of EHR data? (4) What are the challenges and barriers to the development of risk adjusted outcome measures in the EHR environment, and how can these barriers be overcome? Information generated by the conference will form the basis of a demonstration project during which risk adjusted outcome measures useful for monitoring and improving health care quality will be developed and tested using EHR data.
PUBLIC HEALTH RELEVANCE: This conference will address methodological issues that will form the basis for a demonstration project to develop risk-adjusted outcome measures generated from the EHR. It will pave the way for a significant increase in the number of risk-adjusted outcome measures available for oversight, internal quality improvement, public reporting, pay-for-performance and consumer decision-making, across a wider variety of health care settings.
描述(由申请人提供):
我们建议举行一次邀请会议,以研究与电子健康记录(EHR)环境中的结果测量及其伴随的风险调整模型的识别和开发相关的问题。这次会议将解决方法问题,这将构成一个示范项目的基础,以开发从电子健康记录产生的风险调整的结果措施。这些经风险调整的成果措施将有助于监督、内部质量改进、公开报告、按业绩计薪和消费者决策。 结果的措施评估病人的医疗保健系统遇到的结果,他们是特别有用的,以评估该护理的质量。由于难以定位和收集准确而全面的健康结果数据,绩效衡量工作主要集中在护理过程上。然而,在大多数地区,所衡量的护理过程与具体的健康结果之间的关系尚未确定。在广泛的医疗保健领域引入电子健康记录,预计将为访问和收集结果测量所依据的数据提供新的机会。 为了准确地比较各提供者的业绩,随着时间的推移,结果措施需要进行风险调整。结果度量的质量和有用性取决于伴随它的风险调整模型的质量。广泛的EHR实施有望提供更多更好的数据来构建这些模型。 会议将探讨以下问题。(1)如何使用EHR数据为现有的死亡率和再入院结局指标开发风险模型?(2)什么样的EHR数据来源于医院之外,将有助于在医院环境和医院之外的环境中制定风险调整的结局指标?(3)通过使用EHR数据,可以产生哪些新的风险调整结局指标(除了死亡率和再入院率)?(4)在EHR环境中开发风险调整结果指标面临哪些挑战和障碍,以及如何克服这些障碍? 会议产生的信息将构成一个示范项目的基础,在此期间,将使用EHR数据开发和测试用于监测和提高医疗质量的风险调整结果措施。
公共卫生关系:本次会议将讨论方法问题,这些问题将构成一个示范项目的基础,以制定从EHR产生的风险调整结果措施。它将为在更广泛的卫生保健环境中大幅增加可用于监督、内部质量改进、公共报告、按业绩付费和消费者决策的风险调整结果措施铺平道路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen Schmaltz其他文献
Stephen Schmaltz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephen Schmaltz', 18)}}的其他基金
Measurement that Matters: Retooling Risk Adjusted Outcome Measures to Support Practical Data Collection through Electronic Health Records
重要的衡量标准:重组风险调整结果衡量标准以支持通过电子健康记录进行实际数据收集
- 批准号:
9039542 - 财政年份:2015
- 资助金额:
$ 4.97万 - 项目类别:
Measurement that Matters: Retooling Risk Adjusted Outcome Measures to Support Practical Data Collection through Electronic Health Records
重要的衡量标准:重组风险调整结果衡量标准以支持通过电子健康记录进行实际数据收集
- 批准号:
8852893 - 财政年份:2015
- 资助金额:
$ 4.97万 - 项目类别:
相似国自然基金
The Heterogenous Impact of Monetary Policy on Firms' Risk and Fundamentals
- 批准号:
- 批准年份:2024
- 资助金额:万元
- 项目类别:外国学者研究基金项目
基于移动健康技术干预动脉粥样硬化性心血管疾病高危人群的随机对照现场试验:The ASCVD Risk Intervention Trial
- 批准号:81973152
- 批准年份:2019
- 资助金额:54.0 万元
- 项目类别:面上项目
基于时间序列间分位相依性(quantile dependence)的风险值(Value-at-Risk)预测模型研究
- 批准号:71903144
- 批准年份:2019
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
RISK通路在胃泌素介导的心脏缺血再灌注损伤保护中的作用研究
- 批准号:81800239
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
异氟烷基于TLR4/RISK/NF-κB调控糖尿病缺血性脑卒中后NLRP3炎症小体形成的机制研究
- 批准号:81771232
- 批准年份:2017
- 资助金额:54.0 万元
- 项目类别:面上项目
Notch1与RISK/SAFE/HIF-1α信号通路整合在I-postC保护中的作用及其机制
- 批准号:81260024
- 批准年份:2012
- 资助金额:50.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Optimizing the Risk-Adjusted CUSUM for Monitoring Hospital Non-cardiac Perioperative Outcomes
优化风险调整 CUSUM 以监测医院非心脏围手术期结果
- 批准号:
10315667 - 财政年份:2021
- 资助金额:
$ 4.97万 - 项目类别:
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis
ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响
- 批准号:
10292270 - 财政年份:2021
- 资助金额:
$ 4.97万 - 项目类别:
Optimizing the Risk-Adjusted CUSUM for Monitoring Hospital Non-cardiac Perioperative Outcomes
优化风险调整 CUSUM 以监测医院非心脏围手术期结果
- 批准号:
10448264 - 财政年份:2021
- 资助金额:
$ 4.97万 - 项目类别:
Machine learning for risk-adjusted breast MRI screening
用于风险调整乳房 MRI 筛查的机器学习
- 批准号:
10521264 - 财政年份:2020
- 资助金额:
$ 4.97万 - 项目类别:
Machine learning for risk-adjusted breast MRI screening
用于风险调整乳房 MRI 筛查的机器学习
- 批准号:
10316235 - 财政年份:2020
- 资助金额:
$ 4.97万 - 项目类别:
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis
ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响
- 批准号:
9886161 - 财政年份:2018
- 资助金额:
$ 4.97万 - 项目类别:
HNA: Development and evaluation of methods to assess the quality of audit data used to calculate risk-adjusted performance indicators
海航:开发和评估用于计算风险调整绩效指标的审计数据质量的方法
- 批准号:
MR/R013489/1 - 财政年份:2018
- 资助金额:
$ 4.97万 - 项目类别:
Research Grant
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis
ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响
- 批准号:
10372989 - 财政年份:2018
- 资助金额:
$ 4.97万 - 项目类别:
A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
对低危 HPV 相关口咽鳞状细胞癌患者进行择期容量调整降阶梯放射治疗 (EVADER) 的 II 期单臂试验
- 批准号:
379719 - 财政年份:2018
- 资助金额:
$ 4.97万 - 项目类别:
Operating Grants
A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
对低危 HPV 相关口咽鳞状细胞癌患者进行择期容量调整降阶梯放射治疗 (EVADER) 的 II 期单臂试验
- 批准号:
379021 - 财政年份:2017
- 资助金额:
$ 4.97万 - 项目类别:
Operating Grants